Unknown

Dataset Information

0

Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.


ABSTRACT:

Background & aims

It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib. Our study attempted to elucidate the roles of DM/HTN and the effects of diabetes medications among advanced HCC patients receiving sorafenib.

Methods

From August 2012 to February 2018, 733 advanced HCC patients receiving sorafenib were enrolled at China Medical University, Taichung, Taiwan. According to the presence/absence of DM or HTN, they were divided into four groups: control [DM(-)/HTN(-), n = 353], DM-only [DM(+)/HTN(-), n = 91], HTN-only [DM(-)/HTN(+), n = 184] and DM+HTN groups [DM(+)/HTN(+), n = 105]. Based on the types of diabetes medications, there were three groups among DM patients (the combined cohort of DM-only and DM+HTN groups), including metformin (n = 63), non-metformin oral hypoglycemic agent (OHA) (n = 104) and regular insulin (RI)/neutral protamine hagedorn (NPH) groups (n = 29). We then assessed the survival differences between these groups.

Results

DM-only and DM+HTN groups significantly presented longer overall survival (OS) than control group (control vs. DM-only, 7.70 vs. 11.83 months, p = 0.003; control vs. DM+HTN, 7.70 vs. 11.43 months, p = 0.008). However, there was no significant OS difference between control and HTN-only group (7.70 vs. 8.80 months, p = 0.111). Besides, all groups of DM patients showed significantly longer OS than control group (control vs. metformin, 7.70 vs. 12.60 months, p = 0.011; control vs. non-metformin OHA, 7.70 vs. 10.80 months, p = 0.016; control vs. RI/NPH, 7.70 vs. 15.20 months, p = 0.026).

Conclusions

Rather than HTN, DM predicts better prognosis in advanced HCC treated with sorafenib. Besides, metformin, non-metformin OHA and RI/NPH are associated with longer survival among DM-related advanced HCC patients receiving sorafenib.

SUBMITTER: Hsieh MH 

PROVIDER: S-EPMC7775090 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.

Hsieh Ming-Han MH   Kao Tzu-Yu TY   Hsieh Ting-Hui TH   Kao Chun-Chi CC   Peng Cheng-Yuan CY   Lai Hsueh-Chou HC   Chuang Po-Heng PH   Kao Jung-Ta JT  

PloS one 20201231 12


<h4>Background & aims</h4>It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib. Our study attempted to elucidate the roles of DM/HTN and the effects of diabetes medications among advanced HCC patients receiving sorafenib.<h4>Methods</h4>From August 2012 to February 2018, 733 advanced HCC patients receiving sorafenib were enrolled at China Medical University, Taichung, Taiwan. According to t  ...[more]

Similar Datasets

| S-EPMC8199276 | biostudies-literature
| S-EPMC4735679 | biostudies-other
| S-EPMC5016063 | biostudies-literature
| S-EPMC4918283 | biostudies-literature
| S-EPMC7205300 | biostudies-literature
| S-EPMC4857060 | biostudies-literature
| S-EPMC5087301 | biostudies-literature
| S-EPMC7042216 | biostudies-literature
| S-EPMC6973249 | biostudies-literature
| S-EPMC3989951 | biostudies-literature